Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variantRigel Suzuki, Kei Sato|Nature|2022Cited by 748
SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation VariantYoriyuki Konno, Kei Sato|Cell Reports|2020Cited by 438
An emerging SARS-CoV-2 mutant evading cellular immunity and increasing viral infectivityChihiro Motozono, Kei Sato|bioRxiv (Cold Spring Harbor Laboratory)|2021Cited by 74
Virological characteristics of the SARS-CoV-2 Omicron BA.2.75Akatsuki Saito, Kei Sato|bioRxiv (Cold Spring Harbor Laboratory)|2022Cited by 44
Virological characteristics of the SARS-CoV-2 BA.2.86 variantTomokazu Tamura, Kei Sato|bioRxiv (Cold Spring Harbor Laboratory)|2023Cited by 24